Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis
{{output}}
Background: Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system, predominantly presenting as relapsing-remitting MS. Fingolimod decreases relapse rates by lymphocyte sequestration, yet pers... ...
